Effect of Combination Chemotherapy with Cisplatin and Cyclophosphamide on Human Immunodeficiency Virus Type-1 Surrogate Markers in a Patient with Advanced Epithelial Ovarian Cancer

• Published in: Gynecologic oncology Vol. 57; no. 1; pp. 105 - 108
• Main Authors: Fishman, David A., Viscarello, Richard R., Cass, Ilana, Schwartz, Peter E.
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 01-04-1995; Elsevier
• Subjects: Adult; Antineoplastic agents; Biological and medical sciences; Biomarkers - analysis; Chemotherapy; Chemotherapy, Adjuvant; Cisplatin - therapeutic use; Cyclophosphamide - therapeutic use; Cystadenocarcinoma, Serous - complications; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - surgery; Female; HIV Infections - complications; HIV Infections - drug therapy; HIV-1; Humans; Medical sciences; Ovarian Neoplasms - complications; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - surgery; Pharmacology. Drug treatments; Antineoplastic agent; Human; Immunopathology; Carcinoma; Cytostatic; Biological marker; AIDS; Malignant tumor; Uterine cervix; Immune deficiency; Female genital diseases; Infection; Case study; Ovarian diseases; Ovary; Concomitant disease; Chemotherapy; Treatment; Viral disease; Female; Combined treatment; Immunosuppressive agent; Uterine cervix diseases; Platinum II Complexes
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1006/gyno.1995.1105

This is the first report to evaluate the effects of combination chemotherapy on HIV-1 surrogate markers in an HIV-1-infected patient with an advanced epithelial ovarian cancer. Cisplatin combined with cyclophosphamide was well-tolerated, without significant changes in the HIV-1 p24 antigen, neopterin, β2-microglobulin, and CD4 values. The patient demonstrated a chemical and clinical response to therapy, without evidence of opportunistic infection or severe neutropenia. During the 6-month period of observation, treatment with cisplatin and cyclophosphamide did not significantly increase the risk of HIV-1 disease progression.